Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLK Allakos	$0.33	$0.33	$0.22 ▼ $1.56	$29.74M	0.15	1.25 million shs	N/A
COYA Coya Therapeutics	$6.71 +2.3%	$6.10	$4.65 ▼ $10.24	$112.26M	0.26	76,065 shs	53,091 shs
EQ Equillium	$1.82 -4.7%	$0.65	$0.27 ▼ $2.26	$108.29M	1.15	3.48 million shs	1.41 million shs
IOBT IO Biotech	$1.58 -6.0%	$1.73	$0.66 ▼ $2.79	$113.32M	0.44	1.25 million shs	709,666 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLK Allakos	0.00%	0.00%	0.00%	0.00%	-52.99%
COYA Coya Therapeutics	-2.53%	+6.67%	-0.91%	+23.08%	+12.52%
EQ Equillium	-2.05%	+67.54%	+328.64%	+451.86%	+83.65%
IOBT IO Biotech	-2.33%	-10.64%	-30.00%	+38.84%	+5.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLK Allakos	3.3751 of 5 stars	3.2	0.0	4.7	0.0	2.5	1.3
COYA Coya Therapeutics	1.8432 of 5 stars	3.5	2.0	0.0	2.6	0.8	0.0
EQ Equillium	0.9721 of 5 stars	1.0	5.0	0.0	2.7	1.7	0.0
IOBT IO Biotech	3.1221 of 5 stars	3.7	3.0	0.0	2.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLK Allakos	2.33	Hold	$3.00	811.58% Upside
COYA Coya Therapeutics	3.00	Buy	$16.50	145.90% Upside
EQ Equillium	2.00	Hold	$1.00	-45.05% Downside
IOBT IO Biotech	3.33	Buy	$8.67	448.52% Upside

Current Analyst Ratings Breakdown

Latest ALLK, COYA, IOBT, and EQ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/25/2025	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/13/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
8/13/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
8/12/2025	IOBT IO Biotech	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$6.00 ➝ $4.00
7/24/2025	COYA Coya Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00
7/9/2025	COYA Coya Therapeutics	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$16.00
7/1/2025	COYA Coya Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00
6/9/2025	COYA Coya Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$18.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLK Allakos	N/A	N/A	N/A	N/A	$1.93 per share	N/A
COYA Coya Therapeutics	$3.55M	31.62	N/A	N/A	$1.69 per share	3.97
EQ Equillium	$41.10M	2.63	N/A	N/A	$0.08 per share	22.75
IOBT IO Biotech	N/A	N/A	N/A	N/A	$0.71 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLK Allakos	-$185.70M	-$1.32	N/A	N/A	N/A	N/A	-140.87%	-86.22%	N/A
COYA Coya Therapeutics	-$14.88M	-$1.24	N/A	N/A	N/A	N/A	-61.05%	-53.61%	11/5/2025 (Estimated)
EQ Equillium	-$8.07M	-$0.56	N/A	N/A	N/A	-19.62%	-139.56%	-90.56%	11/12/2025 (Estimated)
IOBT IO Biotech	-$95.49M	-$1.58	N/A	N/A	N/A	N/A	-281.82%	-169.29%	11/11/2025 (Estimated)

Latest ALLK, COYA, IOBT, and EQ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	EQ Equillium	-$0.14	-$0.16	-$0.02	-$0.16	N/A	N/A
8/14/2025	Q2 2025	IOBT IO Biotech	-$0.35	-$0.40	-$0.05	-$0.40	N/A	N/A
8/12/2025	Q2 2025	COYA Coya Therapeutics	-$0.22	-$0.36	-$0.14	-$0.36	$0.78 million	$0.16 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLK Allakos	N/A	N/A	N/A	N/A	N/A
COYA Coya Therapeutics	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
IOBT IO Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLK Allakos	N/A	6.08	6.08
COYA Coya Therapeutics	N/A	7.43	7.43
EQ Equillium	N/A	1.65	1.65
IOBT IO Biotech	4.22	1.96	1.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLK Allakos	84.64%
COYA Coya Therapeutics	39.75%
EQ Equillium	27.05%
IOBT IO Biotech	54.76%

Insider Ownership

Company	Insider Ownership
ALLK Allakos	16.12%
COYA Coya Therapeutics	12.00%
EQ Equillium	31.60%
IOBT IO Biotech	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLK Allakos	190	90.38 million	74.94 million	Optionable
COYA Coya Therapeutics	6	16.73 million	14.72 million	Not Optionable
EQ Equillium	40	59.50 million	40.70 million	Not Optionable
IOBT IO Biotech	30	N/A	N/A	Not Optionable

ALLK, COYA, IOBT, and EQ Headlines

Recent News About These Companies

H.C. Wainwright Reiterates Buy Rating on IO Biotech, Keeps PT at $14

August 26 at 10:13 AM | insidermonkey.com

IO Biotech, Inc. (NASDAQ:IOBT) Sees Significant Growth in Short Interest

August 19, 2025 | marketbeat.com

IO Biotech Reports Q2 2025 Financial Results

August 19, 2025 | msn.com

IO Biotech (NASDAQ:IOBT) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS

August 16, 2025 | marketbeat.com

Io Biotech Posts Wider Loss in Q2

August 14, 2025 | aol.comA

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

August 14, 2025 | globenewswire.com

IO Biotech (NASDAQ:IOBT) Price Target Lowered to $4.00 at Morgan Stanley

August 13, 2025 | marketbeat.com

IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma

August 12, 2025 | seekingalpha.com

IO Biotech stock rises as cancer vaccine shows promising results

August 12, 2025 | investing.com

IO Biotech's Phase 3 Trial Fails To Deliver

August 12, 2025 | seekingalpha.com

Mixed results for IO Biotech's cancer vaccine Cylembio

August 12, 2025 | thepharmaletter.comT

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of ...

August 12, 2025 | finance.yahoo.com

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with ...

August 12, 2025 | finance.yahoo.com

IO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10x

August 12, 2025 | msn.com

IO Biotech Shares Climb Following Encouraging Cancer Vaccine Trial Results

August 12, 2025 | msn.com

IO Biotech's cancer vaccine shows improvement, but narrowly misses study goal

August 12, 2025 | msn.com

IO Biotech's Combo Therapy For Skin Cancer Falls Just Short, Eyes FDA Talks Later This Year

August 12, 2025 | benzinga.com

IO Biotech's cancer vaccine shows improvement in late-stage study goal

August 11, 2025 | reuters.com

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

August 11, 2025 | globenewswire.com

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

August 10, 2025 | globenewswire.com

IO Biotech (IOBT) Expected to Announce Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALLK, COYA, IOBT, and EQ Company Descriptions

Allakos NASDAQ:ALLK

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Coya Therapeutics NASDAQ:COYA

$6.71 +0.15 (+2.29%)

Closing price 04:00 PM Eastern

Extended Trading

$6.70 0.00 (-0.07%)

As of 05:31 PM Eastern

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

Equillium NASDAQ:EQ

$1.82 -0.09 (-4.71%)

Closing price 04:00 PM Eastern

Extended Trading

$1.75 -0.07 (-3.85%)

As of 05:36 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

IO Biotech NASDAQ:IOBT

$1.58 -0.10 (-5.95%)

Closing price 04:00 PM Eastern

Extended Trading

$1.58 +0.00 (+0.32%)

As of 05:34 PM Eastern

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time